Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, To Combat Hospital And Community Acquired Superbug Infections, Including MRSA
Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced the presentation of their breakthrough research program to evaluate a new macrolide-related drug class, Bicyclolides, in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and other gram-positive infection pathogens.
More: continued here
Filed under: MRSA / Drug Resistance on April 11th, 2008